Health Care Equipment & Supplies · NYSE

BSXBoston Scientific Corp

Last close
$44.34 +0.3%
52-week range
$39.57 to $104.61
Market cap
$64.3B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$20.1B
+20% vs FY24
Net income
$2.90B
+56% vs FY24
Free cash flow
$3.66B
+38% vs FY24
Net cash
-$9.47B
Cash $1.97B, debt $11.4B

Stock price

+113% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on all 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
18.8x
10.7x278x
22nd percentile, below its median of 62.5x
Positive-earnings quarters only
Price / sales
3.1x
3.0x8.7x
5th percentile, below its median of 5.4x
EV / EBITDA
14.1x
13.5x55.8x
8th percentile, below its median of 30.1x
Price / free cash flow
19.3x
17.4x365x
5th percentile, below its median of 50.0x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
18.8x
Earnings yield
5.3%
Price / sales
3.1x
Price / book
2.5x
Price / operating cash flow
15.2x
EV / EBITDA
14.1x
EV / sales
3.6x
Free cash flow yield
5.2%

Profitability

Gross margin
69.1%
Operating margin
18.7%
Net margin
16.6%
Return on equity
13.7%
Return on capital
10.0%

Growth per year

Revenue, 3 years
+16.5%
Revenue, 5 years
+15.2%
Revenue, 9 years
+10.2%
EPS, 3 years
+62.8%

Balance sheet

Cash and investments
$609M
Total debt
$12.0B
Net cash
-$11.3B
Debt / equity
0.47x
Current ratio
1.36x

Shares and dividend

Shares outstanding
1.45B
Share count, 5 years
+5.5%
Beta, 1 year
0.25
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
n/a

n/a: No dividend

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $5.14B
RevenueNet income
Gross profitLatest quarter $3.43B
EBITDALatest quarter $1.19B
Margins67 / 16 / 11%
GrossOperatingNet
Earnings per shareLatest quarter $0.40
Cash flowLatest quarter $1.05B
OperatingCapexFree
Cash vs debtLatest quarter $609M
Cash and investmentsTotal debt
P/E historyNow 18.8x
P/E, median 62.5x dashed
P/S historyNow 3.1x
P/S, median 5.4x dashed

Where the revenue comes from

EMEA went from 20% to 17% of revenue in 3 years

Share of revenue by region, fiscal 2022 to 2025, as reported in the 10-K.

USEMEAAsia PacificLatin America and Canada
FY22
20%17%
$12.7B
FY23
59%20%17%
$14.2B
FY24
61%19%16%
$16.7B
FY25
64%17%15%
$20.1B
Fiscal 2025 by region
RegionRevenueSharevs FY24
US$12.9B64.1%+26%
EMEA$3.45B17.2%+7%
Asia Pacific$3.08B15.3%+15%
Latin America and Canada$678M3.4%+9%

Health Care Equipment & Supplies peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ABT Abbott Laboratories $188B +10% 13.8%40.4x3.9x 60th percentile
DHR Danaher Corp $164B +6% 20.4%38.1x6.4x 65th percentile
ISRG Intuitive Surgical Inc $154B +20% 28.4%53.7x13.3x 48th percentile
MDT Medtronic plc $132B +10% 18.1%25.3x3.5x 20th percentile
SYK Stryker Corp $118B +8% 20.7%33.0x4.5x 30th percentile
BSX Boston Scientific Corp $64.3B +9% 18.7%18.8x3.1x 22nd percentile

The company

Sector
Health Care
Industry
Health Care Equipment & Supplies
Founded
1979
Headquarters
Marlborough, MA
Fiscal year ends
December
Website
bostonscientific.com

What it does

Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about BSX.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 1,160 active funds. Crowd level: quiet.

Open the Smart money tab